American Century Companies Inc. Has $64.80 Million Stock Position in Pfizer Inc. $PFE

Key Points

• American Century Companies Inc. reduced its stake in Pfizer Inc. by 4.6%, selling 122,607 shares, leaving it with approximately 2.56 million shares valued at $64.8 million.
• Several large investors entered or modified their holdings in Pfizer, with institutional investors currently owning 68.36% of the stock.
• Pfizer recently declared a quarterly dividend of $0.43 per share, translating to an annual yield of 6.9%.

American Century Companies Inc. decreased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 4.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,557,021 shares of the biopharmaceutical company's stock after selling 122,607 shares during the period. American Century Companies Inc.'s holdings in Pfizer were worth $64,795,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Ethic Inc. lifted its stake in shares of Pfizer by 43.2% in the first quarter. Ethic Inc. now owns 643,515 shares of the biopharmaceutical company's stock valued at $15,792,000 after purchasing an additional 194,041 shares during the period. Aberdeen Group plc raised its position in Pfizer by 32.0% during the first quarter. Aberdeen Group plc now owns 4,934,150 shares of the biopharmaceutical company's stock worth $123,280,000 after acquiring an additional 1,196,663 shares during the last quarter. Horizon Investments LLC grew its position in shares of Pfizer by 4.4% in the first quarter. Horizon Investments LLC now owns 86,200 shares of the biopharmaceutical company's stock valued at $2,144,000 after purchasing an additional 3,598 shares during the last quarter. Providence Capital Advisors LLC increased its stake in shares of Pfizer by 1.3% during the 1st quarter. Providence Capital Advisors LLC now owns 115,793 shares of the biopharmaceutical company's stock worth $2,934,000 after purchasing an additional 1,435 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in shares of Pfizer during the 1st quarter worth approximately $3,003,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of recent research reports. The Goldman Sachs Group raised their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Bank of America raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners reduced their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research note on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $28.12.

Pfizer Trading Up 0.9%

PFE stock traded up $0.2250 on Tuesday, hitting $25.2950. 29,134,298 shares of the company were exchanged, compared to its average volume of 45,102,056. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The business's fifty day moving average is $24.64 and its two-hundred day moving average is $24.41. The stock has a market capitalization of $143.82 billion, a price-to-earnings ratio of 13.45, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 earnings per share. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. The ex-dividend date is Friday, July 25th. Pfizer's dividend payout ratio is 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.